e-learning
resources
European Respiratory Review
2018
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence
Luca Richeldi, Francesco Varone, Miguel Bergna, Joao de Andrade, Jeremy Falk, Robert Hallowell, Stéphane Jouneau, Yasuhiro Kondoh, Lee Morrow, Winfried Randerath, Mary Strek, Gabriela Tabaj
Source:
Eur Respir Rev, 27 (150) 180074; 10.1183/16000617.0074-2018
Journal Issue:
December
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Luca Richeldi, Francesco Varone, Miguel Bergna, Joao de Andrade, Jeremy Falk, Robert Hallowell, Stéphane Jouneau, Yasuhiro Kondoh, Lee Morrow, Winfried Randerath, Mary Strek, Gabriela Tabaj. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. Eur Respir Rev, 27 (150) 180074; 10.1183/16000617.0074-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review
Source: ERJ Open Res, 7 (1) 00235-2020; 10.1183/23120541.00235-2020
Year: 2021
Multidisciplinary evaluation of interstitial lung diseases: current insights
Source: Eur Respir Rev, 26 (144) 170002; 10.1183/16000617.0002-2017
Year: 2017
Safety and benefits of beta-blockers in chronic obstructive pulmonary disease: a review of current evidence and meta-analysis
Source: International Congress 2018 – Cardiovascular morbidities in COPD
Year: 2018
Drug induced interstitial lung disease: a systematic review
Source: International Congress 2018 – New insights in rare diffuse parenchymal lung diseases (DPLDs) in adults and children
Year: 2018
Oxygen therapy for interstitial lung disease: a systematic review
Source: Eur Respir Rev 2017; 26: 160080
Year: 2017
Home monitoring of physiology and symptoms to detect interstitial lung disease exacerbations and progression: a systematic review
Source: ERJ Open Res, 7 (4) 00441-2021; 10.1183/23120541.00441-2021
Year: 2021
Treatment of interstitial lung diseases: current approaches and future directions
Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options
Year: 2021
Domiciliary monitoring of physiology and symptoms to detect interstitial lung disease exacerbations and/or progression: a systematic review
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
Diagnosis of interstitial lung diseases and impact of guidelines: an issue only for pulmonologists?
Source: Annual Congress 2007 - Controversies in the management of interstitial lung diseases
Year: 2007
Interstitial lung diseases: a clinical update
Source: Eur Respir J 2001; 18: 1S
Year: 2001
Interstitial lung disease in childhood. A clinical review
Source: Eur Respir J 2004; 24: Suppl. 48, 624s
Year: 2004
Clinical management implications of histologic information provided by lung biopsy in the multidisciplinary evaluation of interstitial lung diseases.
Source: Virtual Congress 2020 – The hot and cold of interventional pulmonology
Year: 2020
Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis
Source: Eur Respir Rev 2012; 21: 48-56
Year: 2012
The clinical efficacy of pulmonary hypertension-specific agents in idiopathic pulmonary fibrosis: A systematic review and meta-analysis
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019
Diffuse parenchymal lung disease: a practical overview Is a lung biopsy necessary for management?
Source: Breathe 2008; 4: 233-239
Year: 2008
Clinical management of the idiopathic interstitial pneumonias: an example of an integrated approach to interstitial lung diseases
Source: Annual Congress 2006 - PG8 - Interstitial lung diseases: idiopathic interstitial pneumonias
Year: 2006
Clinical use of interstitial lung disease guidelines
Source: Eur Respir Mon; 2009: 46: 386–395
Year: 2009
Fibrotic interstitial lung diseases and air pollution: a systematic literature review
Source: Eur Respir Rev, 29 (157) 200093; 10.1183/16000617.0093-2020
Year: 2020
Acute exacerbations of chronic obstructive pulmonary disease: current recommendations review and quality of evidence analysis.
Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept